Keral (Dexketoprofen)

Dexketoprofen blocks cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which lowers the production of prostaglandins. Reduced prostaglandin levels diminish inflammation, pain signalling and fever, resulting in faster analgesic and anti‑inflammatory effects.

The appropriate dose of Keral is determined by the prescribing healthcare professional based on the patient’s condition, age, weight and response. Dosage instructions should always follow the prescriber’s recommendation and local labeling.

Safety of dexketoprofen in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk, and a healthcare provider should be consulted before use in these situations.

To order Keral, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Dexketoprofen is the active enantiomer of ketoprofen and offers a rapid onset of analgesia, often within 30 minutes. Compared with some traditional NSAIDs, it may provide effective pain relief at lower doses, but the safety profile regarding gastrointestinal and cardiovascular risks remains similar to other NSAIDs.

Keral should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

Keral is taken orally, usually with a glass of water. It can be taken with or without food, but if gastrointestinal upset occurs, it may be helpful to take it with a meal. Follow the prescriber’s instructions regarding timing and frequency.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as heart attack or stroke, renal impairment, severe skin reactions, hepatic dysfunction and anaphylaxis. Patients should be monitored for these events, especially if they have pre‑existing risk factors.

Keral should be avoided in patients with known hypersensitivity to dexketoprofen or other NSAIDs, active gastrointestinal ulcer or bleeding, severe heart failure, uncontrolled hypertension, and in those with severe renal or hepatic impairment unless specifically advised by a physician.